ABLi Therapeutics, Inc.

ABLi Therapeutics, Inc., based in Atlanta, GA, is a small biotechnology company focused on developing novel therapeutics primarily targeting neurodegenerative disorders such as multiple system atrophy and Parkinson’s disease as well as infectious diseases like progressive multifocal leukoencephalopathy caused by JC virus reactivation in immunocompromised patients such as those with AIDS. The company has received significant support through US government SBIR/STTR grants totaling over $13 million since its inception around or before 2009. Its pipeline includes preclinical to early clinical candidates involving kinase modulation and anti-infective strategies aimed at high unmet medical needs within neurology and infectious disease domains[1][4][8].